These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36881624)

  • 1. Nasal administration of anti-CD3 mAb (Foralumab) downregulates
    G Moreira T; Gauthier CD; Murphy L; Lanser TB; Paul A; Matos KTF; Mangani D; Izzy S; Rezende RM; Healy BC; Baecher-Allan CM; Chitnis T; Kuchroo V; Weiner HL
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2220272120. PubMed ID: 36881624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects.
    Chitnis T; Kaskow BJ; Case J; Hanus K; Li Z; Varghese JF; Healy BC; Gauthier C; Saraceno TJ; Saxena S; Lokhande H; Moreira TG; Zurawski J; Roditi RE; Bergmark RW; Giovannoni F; Torti MF; Li Z; Quintana F; Clementi WA; Shailubhai K; Weiner HL; Baecher-Allan CM
    Front Immunol; 2022; 13():956907. PubMed ID: 36505477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.
    Moreira TG; Matos KTF; De Paula GS; Santana TMM; Da Mata RG; Pansera FC; Cortina AS; Spinola MG; Baecher-Allan CM; Keppeke GD; Jacob J; Palejwala V; Chen K; Izzy S; Healey BC; Rezende RM; Dedivitis RA; Shailubhai K; Weiner HL
    Front Immunol; 2021; 12():709861. PubMed ID: 34475873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study.
    Moreira TG; Matos KTF; De Paula GS; Santana TMM; Da Mata RG; Pansera FC; Cortina AS; Spinola MG; Baecher-Allan CM; Keppeke GD; Jacob J; Palejwala V; Chen K; Izzy S; Healey BC; Rezende RM; Dedivitis RA; Shailubhai K; Weiner HL
    Front Immunol; 2021; 12():815812. PubMed ID: 35095916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice.
    Ogura M; Deng S; Preston-Hurlburt P; Ogura H; Shailubhai K; Kuhn C; Weiner HL; Herold KC
    Clin Immunol; 2017 Oct; 183():240-246. PubMed ID: 28739191
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Viurcos-Sanabria R; Manjarrez-Reyna AN; Solleiro-Villavicencio H; Rizo-Téllez SA; Méndez-García LA; Viurcos-Sanabria V; González-Sanabria J; Arroyo-Valerio A; Carrillo-Ruíz JD; González-Chávez A; León-Pedroza JI; Flores-Mejía R; Rodríguez-Cortés O; Escobedo G
    Front Immunol; 2022; 13():897995. PubMed ID: 35860236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.
    Ilan Y; Shailubhai K; Sanyal A
    Clin Exp Immunol; 2018 Sep; 193(3):275-283. PubMed ID: 29920654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
    Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
    J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection Effect of Anti-CD3 Monoclonal Antibody on Primo Vessel in Lymph Vessel of Rabbit with Lipopolysaccharide-Induced Inflammation.
    Choi SH; Choi JG; Lee SS
    J Acupunct Meridian Stud; 2022 Feb; 15(1):37-42. PubMed ID: 35770572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
    Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
    Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
    Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Cells Profiles In The Peripheral Blood Of Patients With Moderate To Severe COVID-19 And Healthy Subjects With and Without Vaccination With The Pfizer-BioNTech mRNA Vaccine.
    Al-Attiyah R; Safar HA; Botras L; Botras M; Al-Kandari F; Chehadeh W; Mustafa AS
    Front Immunol; 2022; 13():851765. PubMed ID: 35898494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
    Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
    mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells.
    Wu HY; Quintana FJ; Weiner HL
    J Immunol; 2008 Nov; 181(9):6038-50. PubMed ID: 18941193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Levels of Peripheral CD3
    Aljabr W; Al-Amari A; Abbas B; Karkashan A; Alamri S; Alnamnakani M; Al-Qahtani A
    Microbiol Spectr; 2022 Feb; 10(1):e0084521. PubMed ID: 35196808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.